Mantle-cell lymphoma

Lancet Oncology

Volumn 2, Issue 3, 2001, Pages 141-148

  Barista, Ibrahim ^a   Romaguera, Jorge E ^a   Cabanillas, Fernando ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DIVISION; FORECASTING; GENETICS; HUMAN; MANTLE CELL LYMPHOMA; PROGNOSIS; REVIEW;

CELL DIVISION; FORECASTING; HUMANS; LYMPHOMA, MANTLE-CELL; PROGNOSIS;

EID: 0035296352     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(00)00255-2     Document Type: Review

References (70)

1. Raffeld M., Jaffe E.S. bcl-1, t(11;14), and mantle cell-derived lymphomas. Blood. 78:1991;259-263.
2. Banks P.M., Chan J., Cleary M.L., et al. Mantle cell lymphoma: a proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol. 16:1992;637-640.
3. Harris N.L., Jaffe E.S., Stein H., et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 84:1994;1361-1392.
4. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink H.K., Vardiman J. Lymphoma classification-from controversy to consensus: the REAL and WHO Classification of lymphoid neoplasms. Ann Oncol. 11:(Suppl 1):2000;3-10.
5. Tsujimoto Y., Yunis J., Onorato-Showe L., Erikson J., Nowell P.C., Croce C.M. Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. Science. 224:1984;1403-1406.
6. Laisney V., Nguyen Van C., Gross M.S., Frezal J. Human genes for glutathione S-transferases. Hum Genet. 68:1984;221-227.
7. Russo D., Marie J.P., Zhou D.C., et al. Evaluation of the clinical relevance of the anionic glutathione-S-transferase (GST pi) and multidrug resistance (mdr-1) gene coexpression in leukemias and lymphomas. Leuk Lymphoma. 15:1994;453-468.
8. Bentz M., Plesch A., Bullinger L., et al. t(11;14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer. 27:2000;285-294.
9. Greiner T.C., Moynihan M.J., Chan W.C., et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood. 87:1996;4302-4310.
10. Louie D.C., Offit K., Jaslow R., et al. p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32). Blood. 86:1995;2892-2899.
11. Ott G., Kalla J., Ott M.M., et al. Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood. 89:1997;1421-1429.
12. Monni O., Oinonen R., Elonen E., et al. Gain of 3q and deletion of 11q22 are frequent aberrations in mantle cell lymphoma. Genes Chromosomes Cancer. 21:1998;298-307.
13. Stilgenbauer S., Liebisch P., James M.R., et al. Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.3-923.1 in lymphoproliferative disorders. Proc Natl Acad Sci USA. 93:1996;11837-11841.
14. Clodi K., Snell V., Zhao S., Cabanillas F., Andreeff M., Younes A. Unbalanced expression of Fas and CD40 in mantle cell lymphoma. Br J Haematol. 103:1998;217-219.
15. Aguilera N.S., Chu W.S., Andriko J.A., Abbondanzo S.L. Expression of CD44 (HCAM) in small lymphocytic and mantle cell lymphoma. Hum Pathol. 29:1998;1134-1139.
16. Jacob M.C., Agrawal S., Chaperot L., et al. Quantification of cellular adhesion molecules on malignant B cells from non-Hodgkin's lymphoma. Leukemia. 13:1999;1428-1433.
17. Geissmann F., Ruskone-Fourmestraux A., Hermine O., et al. Homing receptor α4β7 integrin expression predicts digestive tract involvement in mantle cell lymphoma. Am J Pathol. 153:1998;1701-1705.
18. Zucca E., Stein H., Coiffier B. European Lymphoma Task Force (ELTF): Report of the workshop on mantle cell lymphoma (MCL). Ann Oncol. 5:1994;507-511.
19. Daniel M.T., Tigaud I., Flexor M.A., Nogueira M.E., Berger R., Jonveaux P. Leukaemic non-Hodgkin's lymphomas with hyperdiploid cells and t(11;14)(q13;q32): a subtype of mantle cell lymphoma? Br J Haematol. 90:1995;77-84.
20. de Boer C.J., Loyson S., Kluin P.M., Kluin-Nelemans H.C., Schuuring E., van Krieken J.H. Multiple breakpoints within the BCL-1 locus in B-cell lymphoma: rearrangements of the cyclin D1 gene. Cancer Res. 53:1993;4148-4152.
21. Williams M.E., Swerdlow S.H., Meeker T.C. Chromosome t(11;14)(q13;q32) breakpoints in centrocytic lymphoma are highly localized at the bcl-1 major translocation cluster. Leukemia. 7:1993;1437-1440.
22. Medeiros L.J., Van Krieken J.H., Jaffe E.S., Raffeld M. Association of bcl-1 rearrangements with lymphocytic lymphoma of intermediate differentiation. Blood. 76:1990;2086-2090.
23. Luthra R., Hai S., Pugh W.C. Polymerase chain reaction detectionof the t(11;14) translocation involving the bcl-1 majortranslocation cluster in mantle cell lymphoma. Diagn Mol Pathol. 4:1995;4-7.
24. Li J.Y., Gaillard F., Moreau A., et al. Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization. Am J Pathol. 154:1999;1449-1452.
25. Katz R.L., Caraway N.P., Gu J., et al. Detection of chromosome 11q13 breakpoints by interphase fluorescence in situ hybridization: a useful ancillary method for the diagnosis of mantle cell lymphoma. Am J Clin Pathol. 114:2000;248-257.
26. Williams M.E., Swerdlow S.H. Cyclin D1 overexpression in non-Hodgkin's lymphoma with chromosome 11 bcl-1 rearrangement. Ann Oncol. 5:(Suppl 1):1994;71-73.
27. Bosch F., Jares P., Campo E., et al. PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood. 84:1994;2726-2732.
28. de Boer C.J., Schuuring E., Dreef E., et al. Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma. Blood. 86:1995;2715-2723.
29. Teodorovic I., Pittaluga S., Kluin-Nelemans J.C., et al. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. J Clin Oncol. 13:1995;2819-2826.
30. Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients. Ann Oncol. 8:1997;973-978.
31. Samaha H., Dumontet C., Ketterer N., et al. Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia. 12:1998;1281-1287.
32. Decaudin D., Salanoubat C., Carde P. Is mantle cell lymphoma a sex-related disease? Leuk Lymphoma. 37:2000;181-184.
33. Duggan M.J., Weisenburger D.D., Ye Y.L., et al. Mantle zone lymphoma: a clinicopathologic study of 22 cases. Cancer. 66:1990;522-529.
34. Oinonen R., Franssila K., Elonen E. Spontaneous splenic rupture in two patients with a blastoid variant of mantle cell lymphoma. Ann Hematol. 74:1997;33-35.
35. Romaguera J., Dang N., Hagemeister F.B., et al. Evidence for need of upper and lower endoscopies with biopsy in staging of asymptomatic patients with aggressive mantle cell lymphoma (MCL). Blood (abstr 1440). 96:2000;334a.
36. Lavergne A., Brouland J.P., Launay E., Nemeth J., Ruskone-Fourmestraux A., Galian A. Multiple lymphomatous polyposisof the gastrointestinal tract: an extensive histopathologic and immunohistochemical study of 12 cases. Cancer. 74:1994;3042-3050.
37. Oinonen R., Franssila K., Elonen E. Central nervous system involvement in patients with mantle cell lymphoma. Ann Hematol. 78:1999;145-149.
38. Montserrat E., Bosch F., Lopez-Guillermo A., et al. CNS involvement in mantle-cell lymphoma. J Clin Oncol. 14:1996;941-944.
39. Argatoff L.H., Connors J.M., Klasa R.J., Horsman D.E., Gascoyne R.D. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood. 89:1997;2067-2078.
40. Porcu P., Nichols C.R. Evaluation and management of the "new" lymphoma entities: mantle cell lymphoma, lymphoma of mucosa-associated lymphoid tissue, anaplastic large-cell lymphoma, and primary mediastinal B-cell lymphoma. Curr Prob Cancer. 22:1998;283-368.
41. Fisher R.I., Dahlberg S., Nathwani B.N., Banks P.M., Miller T.P., Grogan T.M. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood. 85:1995;1075-1082.
42. Meusers P., Engelhard M., Bartels H., et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol. 7:1989;365-380.
43. Berger F., Felman P., Sonet A., et al. Nonfollicular small B-cell lymphomas: a heterogeneous group of patients with distinct clinical features and outcome. Blood. 83:1994;2829-2835.
44. Zucca E., Roggero E., Pinotti G., et al. Patterns of survival in mantle cell lymphoma. Ann Oncol. 6:1995;257-262.
45. Norton A.J., Matthews J., Pappa V., et al. Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20-year period. Ann Oncol. 6:1995;249-256.
46. Velders G.A., Kluin-Nelemans J.C., De Boer C.J., et al. Mantle-cell lymphoma: a population-based clinical study. J Clin Oncol. 14:1996;1269-1274.
47. Decaudin D., Bosq J., Munck J.N., et al. Mantle cell lymphomas: characteristics, natural history and prognostic factors of 45 cases. Leuk Lymphoma. 26:1997;539-550.
48. Vandenberghe E., De Wolf-Peeters C., Vaughan Hudson G., et al. The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group. Br J Haematol. 99:1997;842-847.
49. Majlis A., Pugh W.C., Rodriguez M.A., Benedict W.F., Cabanillas F. Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants. J Clin Oncol. 15:1997;1664-1671.
50. Bosch F., Lopez-Guillermo A., Campo E., et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer. 82:1998;567-575.
51. Hiddemann W., Unterhalt M., Herrmann R., et al. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol. 16:1998;1922-1930.
52. Oinonen R., Franssila K., Teerenhovi L., Lappalainen K., Elonen E. Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients. Eur J Cancer. 34:1998;329-336.
53. Ketterer N., Salles G., Espinouse D., et al. Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma. Ann Oncol. 8:1997;701-704.
54. Blay J.Y., Sebban C., Surbiguet C., et al. High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin's lymphomas: a single center experience on 18 patients. Bone Marrow Transplant. 21:1998;51-54.
55. Conde A., Bosch F., Arranz R., et al. Autologous stem cell transplantation for mantle cell lymphoma (MCL). The experience of the GEL/TAMO Spanish Cooperative Group. Blood (abstr 1915). 92:(Suppl 1):1915;464a.
56. Decaudin D., Brousse N., Brice P., et al. Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study. Bone Marrow Transplant. 25:2000;251-256.
57. Andersen N.S., Donovan J.W., Borus J.S., et al. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood. 90:1997;4212-4221.
58. Khouri I.F., Lee M.S., Romaguera J., et al. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Ann Oncol. 10:1999;1293-1299.
59. Khouri I.F., Romaguera J., Kantarjian H., et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol. 16:1998;3803-3809.
60. Romaguera J.E., Khouri I.F., Kantarjian H.M., et al. Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma. 39:2000;77-85.
61. Lardelli P., Bookman M.A., Sundeen J., Longo D.L., Jaffe E.S. Lymphocytic lymphoma of intermediate differentiation: morphologic and immunophenotypic spectrum and clinical correlations. Am J Surg Pathol. 14:1990;752-763.
62. Coiffier B., Haioun C., Ketterer N., et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 92:1998;1927-1932.
63. Foran J.M., Rohatiner A.Z., Cunningham D., et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody)for patients with newly diagnosed mantle-cell lymphomaand previously treated mantle-cell lymphoma, immunocytoma,and small B-cell lymphocytic lymphoma. J Clin Oncol. 18:2000;317-324.
64. Howard O., Gribben J., Neuberg D., et al. Rituxan/CHOP induction therapy in newly diagnosed patients with mantle cell lymphoma. Blood (abstr 2804). 94:1999;631a.
65. Younes A., Ayoub J.P., Sarris A., et al. Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. Br J Haematol. 96:1997;328-332.
66. Decaudin D., Bosq J., Tertian G., et al. Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas. J Clin Oncol. 16:1998;579-583.
67. Foran J.M., Rohatiner A.Z., Coiffier B., et al. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol. 17:1999;546-553.
68. Zinzani P.L., Magagnoli M., Moretti L., et al. Fludarabine-based chemotherapy in untreated mantle cell lymphomas: an encouraging experience in 29 patients. Haematologica. 84:1999;1002-1006.
69. Rummel M.J., Chow K.U., Jager E., et al. Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas. Leuk Lymphoma. 35:1999;129-138.
70. Cohen B.J., Hedrick E., Moskowitz C., Straus D.J., Zelenetz A.D. The cyclophosphamide/fludarabine (CF) regimen in mantle cell lymphoma (MCL). Proc Am Soc Clin Oncol (abstr 50). 19:2000;15a.